TCRT - Alaunos Therapeutics, Inc. Stock Price, Fair Value and News

1.32USD-0.04 (-2.94%)Market Closed

Market Summary

USD1.32-0.04

Market Closed

-2.94%

TCRT Stock Price

View Fullscreen

TCRT RSI Chart

TCRT Valuation

Market Cap

21.8M

Price/Earnings (Trailing)

-0.62

Price/Sales (Trailing)

4.4K

Price/Free Cashflow

-0.72

TCRT Price/Sales (Trailing)

TCRT Profitability

Return on Equity

-557.16%

Return on Assets

-425.27%

Free Cashflow Yield

-139.32%

TCRT Fundamentals

TCRT Revenue

Revenue (TTM)

5.0K

TCRT Earnings

Earnings (TTM)

-35.1M

Earnings Growth (Yr)

14.37%

Earnings Growth (Qtr)

7.47%

Breaking Down TCRT Revenue

Last 7 days

16.4%

Last 30 days

-23.3%

Last 90 days

-39.2%

Trailing 12 Months

-84.7%

How does TCRT drawdown profile look like?

TCRT Financial Health

Current Ratio

4.22

TCRT Investor Care

Buy Backs (1Y)

93.35%

Diluted EPS (TTM)

-2.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	2.2M	1.1M	5.0K
2022	0	0	3.3M	3.3M
2021	0	0	272.0K	398.0K
2018	4.8M	3.3M	1.7M	146.0K
2017	6.5M	6.4M	6.4M	6.4M
2016	6.0M	7.5M	7.2M	6.9M
2015	1.4M	1.5M	2.8M	4.3M
2014	800.0K	800.0K	1.2M	1.4M
2013	800.0K	800.0K	800.0K	800.0K
2012	800.0K	800.0K	800.0K	800.0K
2011	0	0	0	667.0K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Alaunos Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 01, 2023	boyle kevin s. sr.	sold	-9,542	0.1403	-68,014	chief executive officer
Nov 29, 2022	postma robert w	bought	487,500	0.65	750,000	-
Nov 29, 2022	vieser jaime	bought	812,500	0.65	1,250,000	-
Aug 30, 2022	boyle kevin s. sr.	sold (taxes)	-45,187	2.41	-18,750	chief executive officer
Jun 22, 2022	thistle mary	acquired	-	-	40,000	-
Jun 22, 2022	huang james	acquired	-	-	80,000	-
Jun 22, 2022	bowden christopher	acquired	-	-	40,000	-
Jun 22, 2022	postma robert w	acquired	-	-	40,000	-
Jun 22, 2022	vieser jaime	acquired	-	-	40,000	-
Jun 22, 2022	weis holger	acquired	-	-	40,000	-

Which funds bought or sold TCRT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	MAGNOLIA CAPITAL ADVISORS LLC	sold off	-100	-65,446	-	-%
May 02, 2024	Mutual Advisors, LLC	sold off	-100	-1,916	-	-%
May 02, 2024	MAGNOLIA CAPITAL ADVISORS LLC	new	-	27,658	27,658	0.02%
May 01, 2024	Janney Montgomery Scott LLC	sold off	-100	-3,000	-	-%
May 01, 2024	StoneX Group Inc.	sold off	-100	-2,000	-	-%
May 01, 2024	Key Financial Inc	sold off	-100	-261	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	sold off	-100	-3,669	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	new	-	6,261	6,261	-%

Are Funds Buying or Selling TCRT?

Are funds buying TCRT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TCRT

No. of Funds

Unveiling Alaunos Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	discovery capital management, llc / ct	1.66%	4,001,856	SC 13G/A
Feb 13, 2024	msd partners, l.p.	9.2%	22,727,274	SC 13G/A
Feb 14, 2023	discovery capital management, llc / ct	6.73%	16,185,998	SC 13G/A
Feb 14, 2023	msd partners, l.p.	7.0%	15,151,516	SC 13G/A
Feb 09, 2023	vanguard group inc	3.81%	9,147,741	SC 13G/A
Jan 20, 2023	state street corp	0.33%	782,025	SC 13G/A
Jul 08, 2022	blackrock inc.	2.4%	5,237,799	SC 13G
Feb 14, 2022	discovery capital management, llc / ct	6.17%	13,346,493	SC 13G/A
Feb 11, 2022	state street corp	6.16%	13,318,734	SC 13G
Feb 11, 2022	hardie robert d.	4.8%	10,266,937	SC 13G/A

Recent SEC filings of Alaunos Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 15, 2024	PRE 14A	PRE 14A
Apr 01, 2024	10-K	Annual Report
Feb 28, 2024	3	Insider Trading
Feb 22, 2024	8-K	Current Report
Feb 20, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Alaunos Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	21.21%	-3.50%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-1.57%	-9.52%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	3.97%	-34.13%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	1.98%	349.41%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-3.22%	25.10%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-29.72%	84.40%	-0.25	2.14	-13.45%	66.37%

Alaunos Therapeutics, Inc. News

Latest updates

Alaunos Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2021Q4	2021Q3	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3
Revenue	-76.9%	1.00	4.00	8.00	11.00	2,911	-	398	-	-	532	1,065	1,597	1,598	1,597	1,597	1,597	1,598	1,697	1,969	1,919	1,869
Operating Expenses	-8.2%	7,950	8,664	7,986	8,533	11,175	11,051	22,694	12,762	12,570	12,378	16,342	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-32.1%	2,428	3,578	3,045	2,926	3,282	2,095	8,173	4,563	4,307	4,889	6,159	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-74.5%	933	3,656	5,186	5,608	7,893	8,216	14,521	8,199	8,263	7,489	10,183	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	1,068	889	841	745	444	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	7.5%	-7,843	-8,476	-8,773	-9,159	-8,851	-11,794	-22,733	194,538	-18,659	-17,493	-21,140	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-21298.6%	-7.03	-32.84*	-16.63*	-11.36*	-12.20*	-197.87*	-329.89*	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-15.8%	-7,385	-6,375	-7,137	-7,246	-6,159	-15,485	-9,947	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-57.5%	8.00	19.00	28.00	49.00	65.00	67.00	74.00	85.00	95.00	114	107	128	146	166	182	198	109	118	73.00	84.00	95.00
Current Assets	-35.8%	8.00	13.00	19.00	38.00	54.00	56.00	61.00	70.00	79.00	97.00	89.00	113	131	155	173	192	105	116	66.00	74.00	84.00
Cash Equivalents	-49.2%	6.00	12.00	18.00	23.00	39.00	52.00	60.00	68.00	76.00	92.00	77.00	100	115	135	154	171	80.00	88.00	44.00	51.00	62.00
Net PPE	-100.0%	0.00	6.00	7.00	8.00	8.00	9.00	10.00	10.00	11.00	12.00	12.00	11.00	10.00	8.00	6.00	4.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-64.7%	2.00	6.00	6.00	19.00	26.00	35.00	34.00	36.00	37.00	45.00	18.00	23.00	22.00	21.00	18.00	18.00	14.00	12.00	11.00	9.00	9.00
Current Liabilities	-58.2%	2.00	5.00	5.00	17.00	24.00	33.00	27.00	21.00	16.00	28.00	14.00	19.00	18.00	19.00	17.00	17.00	13.00	11.00	10.00	8.00	9.00
Long Term Debt	-	-	-	-	-	-	-	4.00	10.00	16.00	12.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	11.00	17.00	23.00	20.00	14.00	8.00	12.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	4.00	10.00	16.00	12.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-54.6%	6.00	14.00	22.00	30.00	39.00	32.00	40.00	49.00	58.00	69.00	88.00	106	124	145	163	180	95.00	106	62.00	74.00	86.00
Retained Earnings	-0.9%	-915	-907	-899	-890	-880	-871	-862	-852	-842	-831	-808	-785	-764	-741	-721	-702	-684	-668	-594	-579	-566
Additional Paid-In Capital	0.1%	922	922	921	920	919	903	903	902	901	900	896	891	888	886	884	883	779	774	656	654	652
Shares Outstanding	-93.3%	16.00	241	241	241	240	215	215	215	216	215	214	214	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	222	-	-	-	543,706	-	-	-	687	-	-	-	835	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-15.9%	-7,385	-6,374	-7,002	-9,381	-7,130	-6,145	-8,187	-7,770	-15,126	-9,577	-21,452	-15,313	-17,036	-16,065	-14,006	-9,906	-11,608	-10,927	-8,087	-10,232	-11,819
Share Based Compensation	-65.6%	250	726	914	910	877	808	990	853	917	2,371	5,290	2,197	1,436	1,792	1,661	1,940	1,600	1,486	1,799	1,456	684
Cashflow From Investing	150200.0%	1,503	1.00	-135	-23.00	-93.00	-14.00	-57.00	-29.00	-359	-370	-1,877	-717	-3,766	-2,012	-3,487	-513	-100	-107	-67.00	-10.00	86.00
Cashflow From Financing	-	-	-	-11,980	-6,158	8,474	-2,107	-	-	-186	24,926	19.00	1,017	400	27.00	12.00	101,680	3,030	55,890	230	-	41,346
Buy Backs	-	-	-	-	-	-	45.00	-	-	-	-	-	-	-	-	-	-	283	-	-	370	347

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TCRT Income Statement

2023-12-31

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 5	$ 2,922
Operating expenses:
Research and development	16,279	25,018
General and administrative	12,219	13,142
Gain on lease modification and termination	(298)	(133)
Restructuring costs	1,269	0
Property and equipment and right-of-use assets impairment	4,803	0
Total operating expenses	34,272	38,027
Loss from operations	(34,267)	(35,105)
Other income (expense):
Interest expense	(1,921)	(3,154)
Other income , net	1,048	529
Other income (expense), net	(873)	(2,625)
Net loss	$ (35,140)	$ (37,730)
Earnings per share, Basic	$ (2.2)	$ (2.61)
Earnings per share, Diluted	$ (2.2)	$ (2.61)
Weighted average common shares outstanding, basic	15,995,323	14,475,354
Weighted average common shares outstanding, diluted	15,995,323	14,475,354

TCRT Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,062	$ 39,058
Restricted cash	0	13,938
Receivables	1	4
Prepaid expenses and other current assets	2,198	799
Total current assets	8,261	53,799
Property and equipment, net	2	8,460
Right-of-use assets	0	2,136
Deposits	0	42
Other non-current assets	0	500
Total assets	8,263	64,937
Current liabilities:
Accounts payable	616	1,389
Current portion of long-term debt	0	16,765
Accrued expenses	1,340	5,454
Lease liabilities, current	0	558
Total current liabilities	1,956	24,166
Lease liabilities, non-current	0	2,188
Other non-current liabilities	0	28
Total liabilities	1,956	26,382
Commitments and contingencies (Note 9)
Stockholders' equity:
Common stock $0.001 par value; 34,666,667 shares authorized, 16,012,522 shares issued and outstanding at December 31, 2023 and 28,000,000 shares authorized,16,027,384 shares issued and outstanding at December 31, 2022	16	16
Additional paid-in capital	922,058	919,166
Accumulated deficit	(915,767)	(880,627)
Total stockholders' equity	6,307	38,555
Total liabilities and stockholders' equity	$ 8,263	$ 64,937

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

CEO	Mr. Kevin S. Boyle Sr.
WEBSITE	alaunos.com
INDUSTRY	Biotechnology
EMPLOYEES	34

Alaunos Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Alaunos Therapeutics, Inc.? What does TCRT stand for in stocks?

TCRT is the stock ticker symbol of Alaunos Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alaunos Therapeutics, Inc. (TCRT)?

As of Thu May 02 2024, market cap of Alaunos Therapeutics, Inc. is 21.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TCRT stock?

You can check TCRT's fair value in chart for subscribers.

What is the fair value of TCRT stock?

You can check TCRT's fair value in chart for subscribers. The fair value of Alaunos Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alaunos Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TCRT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alaunos Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TCRT is over valued or under valued. Whether Alaunos Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Alaunos Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TCRT.

What is Alaunos Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, TCRT's PE ratio (Price to Earnings) is -0.62 and Price to Sales (PS) ratio is 4.36 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TCRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alaunos Therapeutics, Inc.'s stock?

In the past 10 years, Alaunos Therapeutics, Inc. has provided -0.303 (multiply by 100 for percentage) rate of return.